Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis.

BMC Ophthalmol · 2023 · PMC9881324 · PMID 36707779

Europe PMC DOI

hedged sentences

0.0560

closest p · 1.1× alpha

0.0670

boldest claim

The sentences

borderline significantP = 0.056so close (0.05 < p ≤ 0.1)

A borderline significant difference in BCVA changes remained consistent between the two subgroups at Month 12 ( P = 0.056).

also in 11,409 other papers

borderline significanceP = 0.067so close (0.05 < p ≤ 0.1)

Baseline BCVA was also comparable between the subgroups; however, baseline CRT was numerically higher in the ≥ 5-letter gain subgroup with borderline significance ( P = 0.067) (Table 1 ).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.